Brind.
  1. FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership.

Novavax and Sanofi announced a partnership to facilitate vaccine access.

3 reports, 3 independent Updated Aug 28
Gone quiet Reached 3 outlets in its first 24 hours
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Novavax and Sanofi announced a partnership to facilitate vaccine access.

Who's involved

What this event is mainly about
NovavaxSanofi

How it developed

Newest first. Tap a step to see who reported it.
  1. Novavax and Sanofi partner for vaccine access.1 source
  2. Novavax licensed its COVID-19 shot to Sanofi.1 source

Keep exploring

Part of

FDA approved Novavax's Nuvaxovid BLA, leading to Sanofi receiving a milestone payment and taking over U.S. commercial leadership. All 1 developments

The entities involved

  • Novavax

    company in Gaithersburg, Maryland

    Nothing else this week.

  • Sanofi

    company in Milan, Italy

    Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped
  • PR NewswireNovavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S. Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
  • Insider MonkeyNovavax Strengthens Position with Vaccine Approval and Sanofi Partnership Novavax, Inc. (NASDAQ:NVAX) is one of the 11 Best Short Squeeze Stocks to Buy Now. The company’s non-mRNA COVID-19 vaccine is
  • ReutersNovavax banks on vaccine supply partnerships to boost 2025 revenue By Mariam Sunny (Reuters) -Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine s